Rakuten Medical Raises $100 Million in Oversubscribed Series F for Photoimmunotherapy Platform

Rakuten Medical raised $100 million in an oversubscribed Series F funding round to accelerate development toward U.S. regulatory approval for its precision photoimmunotherapy platform.4

The company develops light-activated cancer treatments targeting head and neck cancer using its proprietary Alluminox cell-targeting therapies platform.12

This follows prior raises including $119M Series E in March 2024, bringing total funding to nearly $738M, with investors like Rakuten Group and Hikma Pharmaceuticals.23

Recent announcement aligns with preparations for the J.P. Morgan Healthcare Conference presentation on January 15, 2026.5

Sources:

1. https://www.bioworld.com/articles/377996-rakuten-invests-100m-to-expand-light-activated-cancer-drug-platform

2. https://news.crunchbase.com/venture/biggest-funding-rounds-ai-biotech-alumis/

3. https://www.drugdiscoverytrends.com/20-biotech-startups-attracted-almost-3b-in-q1-2024-funding/

4. https://www.prnewswire.com/news-releases/financial-services-latest-news/venture-capital-list/

5. https://leadiq.com/c/rakuten-medical/5a1d8aa12400002400647ac5